Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 5,919 Shares

Posted by Tristan Rich on May 20th, 2025

Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc purchased 5,919 shares of the firm’s stock in a transaction on Monday, May 19th. The shares were acquired at an average cost of $11.78 per share, for a total transaction of $69,725.82. Following the completion of the acquisition, the director now owns 17,883,908 shares of the company’s stock, valued at approximately $210,672,436.24. This trade represents a 0.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

On Thursday, May 15th, Ecor1 Capital, Llc acquired 49,502 shares of Zymeworks stock. The shares were purchased at an average price of $11.43 per share, with a total value of $565,807.86.
On Wednesday, April 16th, Ecor1 Capital, Llc acquired 73,953 shares of Zymeworks stock. The shares were purchased at an average price of $11.16 per share, with a total value of $825,315.48.
On Friday, April 4th, Ecor1 Capital, Llc acquired 196,438 shares of Zymeworks stock. The shares were purchased at an average price of $11.17 per share, with a total value of $2,194,212.46.
On Wednesday, April 2nd, Ecor1 Capital, Llc acquired 74,360 shares of Zymeworks stock. The shares were purchased at an average price of $11.85 per share, with a total value of $881,166.00.
On Monday, March 31st, Ecor1 Capital, Llc acquired 4,397 shares of Zymeworks stock. The shares were purchased at an average price of $11.75 per share, with a total value of $51,664.75.
On Wednesday, March 26th, Ecor1 Capital, Llc acquired 43,848 shares of Zymeworks stock. The shares were purchased at an average price of $12.24 per share, with a total value of $536,699.52.
On Monday, March 24th, Ecor1 Capital, Llc purchased 22,689 shares of Zymeworks stock. The stock was bought at an average price of $13.08 per share, with a total value of $296,772.12.
On Friday, March 21st, Ecor1 Capital, Llc purchased 31,033 shares of Zymeworks stock. The stock was bought at an average price of $12.78 per share, with a total value of $396,601.74.
On Wednesday, March 19th, Ecor1 Capital, Llc purchased 58,306 shares of Zymeworks stock. The stock was bought at an average price of $12.64 per share, with a total value of $736,987.84.
On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The stock was bought at an average price of $12.23 per share, with a total value of $688,267.71.

Zymeworks Stock Performance

Zymeworks stock opened at $11.82 on Tuesday. The company has a 50 day moving average price of $11.81 and a 200-day moving average price of $13.37. Zymeworks Inc. has a fifty-two week low of $8.21 and a fifty-two week high of $17.70. The company has a market capitalization of $822.40 million, a PE ratio of -7.88 and a beta of 1.24.

Zymeworks (NYSE:ZYME – Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The firm had revenue of $27.11 million during the quarter, compared to the consensus estimate of $20.65 million. During the same quarter in the previous year, the firm posted ($0.42) earnings per share. The company’s revenue was up 170.3% on a year-over-year basis. On average, analysts forecast that Zymeworks Inc. will post -1.39 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently commented on ZYME. Citigroup lifted their price target on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, March 7th. Lifesci Capital initiated coverage on Zymeworks in a research report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 target price for the company. Finally, HC Wainwright boosted their target price on Zymeworks from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Zymeworks presently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Read Our Latest Report on ZYME

Hedge Funds Weigh In On Zymeworks

A number of large investors have recently bought and sold shares of the business. Nuveen Asset Management LLC raised its stake in Zymeworks by 0.4% in the fourth quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock worth $3,031,000 after buying an additional 886 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Zymeworks by 6.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company’s stock worth $214,000 after buying an additional 940 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in Zymeworks by 12.7% in the first quarter. Janney Montgomery Scott LLC now owns 11,567 shares of the company’s stock worth $138,000 after buying an additional 1,300 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Zymeworks by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock worth $386,000 after buying an additional 1,427 shares in the last quarter. Finally, Picton Mahoney Asset Management raised its stake in Zymeworks by 0.7% in the first quarter. Picton Mahoney Asset Management now owns 208,029 shares of the company’s stock worth $2,477,000 after buying an additional 1,460 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.